Inhak Choi

Prof. Inhak Choi

Department of Microbiology and Immunology, Inje University, College of Medicine, Busan, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2012 in Hepatology
Verified
Journal Article
Open access
PDF file
KJKeunok Jung
Keunok Jung
MKMiseon Kang
Miseon Kang
CPCheol Park
Cheol Park
YCYung Hyun Choi
Yung Hyun Choi
YJYoukyung Jeon
Youkyung Jeon
Inhak ChoiInhak Choi
Inhak Choi
V-set and Ig domain-containing 4 (VSIG4, CRIg, or Z39Ig), a newly identified B7-related cosignaling molecule, is a complement receptor and a coinhibitory ligand that negatively regulates T-cell immunity. Despite its exclusive expression on liver Kupffer cells (KCs) that play key roles in liver tolerance, the physiological role of VSIG4 in liver tolerance remains undefined. Mice lacking VSIG4 had poor survival rates and severe liver pathology in a concanavalin A (ConA)-induced hepatitis (CIH) model, which could be prevented by adoptive transfer of VSIG4+ KCs. The absence of VSIG4 rendered endogenous liver T- and natural killer T (NKT)-cells more responsive to antigen-specific stimulation and impaired tolerance induction in those cells against their cognate antigens. T-cell costimulation with VSIG4.Ig suppressed Th1-, Th2-, and Th17-type cytokine production and arrested the cell cycle at the G0/G1 phase but did not induce apoptosis in vitro . VSIG4-mediated tolerance induction and cell-cycle arrest were further supported by down-regulation of G1 phase-specific Cdk2, Cdk4, and Cdk6, and up-regulation of tolerance-inducing p27KIP-1 in VSIG4.Ig-stimulated T-cells. Administration of soluble VSIG4.Ig to wildtype mice prevented CIH development and prolonged the survival of mice with established CIH. Conclusion: Collectively, our results suggest that VSIG4+ KCs play a critical role in the induction and maintenance of liver T- and NKT-cell tolerance, and that modulation of the VSIG4 pathway using a VSIG4.Ig fusion protein may provide useful immunological therapies against immune-mediated liver injury including autoimmune hepatitis.

1 January 2013 in Immune Network
Verified
Journal Article
Open access
PDF file
KJKeunok Jung
Keunok Jung
Inhak ChoiInhak Choi
Inhak Choi
Jung K, et al. Immune Netw. 2013 Oct;13(5):184-193. https://doi.org/10.4110/in.2013.13.5.184

25 October 2007 in Immunology
Verified
Journal Article
Open access
PDF file
SSSu‐Kil Seo
Su‐Kil Seo
HJHye‐Young Jeong
Hye‐Young Jeong
SPSae‐Gwang Park
Sae‐Gwang Park
SLSoo‐Woong Lee
Soo‐Woong Lee
ICIl‐Whan Choi
Il‐Whan Choi
Inhak ChoiInhak Choi
Inhak Choi
Summary: B7‐H1 (also known as CD274 and PD‐L1) is a cosignalling molecule regulating T‐cell immunity positively or negatively in vivo. However, little is known about the role of endogenous B7‐H1 in bacterial infection. We found that B7‐H1 expression was up‐regulated in various cell populations including CD4+ and CD8+ T cells, natural killer (NK) cells and macrophages following Listeria monocytogenes infection. Administration of the antagonistic B7‐H1 monoclonal antibody resulted in a significant increase in mortality in mice infected with a lethal dose of L. monocytogenes compared with mice given the control immunoglobulin. In vivo blockade of B7‐H1 greatly inhibited the production of tumour necrosis factor (TNF)‐α and nitric oxide, key effector molecules responsible for intracellular killing by macrophages. B7‐H1 blockade also suppressed the expression of granzyme B and interferon (IFN)‐γ by NK cells. Interestingly, blocking of endogenous B7‐H1 selectively inhibited CD8+ T cells rather than CD4+ T cells in response to L. monocytogenes infection, as evidenced by the reduction of IFN‐γ production and the expression of effector surface markers including CD62Lint/low and CD44high in CD8+ T cells from mice given anti‐B7‐H1 monoclonal antibody. In addition, we found that the proliferation of listeriolysin‐O (LLO)‐specific and IFN‐γ‐producing L. monocytogenes‐reactive CD8+ T cells was significantly decreased not only in the effector phase but also in the memory phase in the presence of anti‐B7‐H1 antibody. Our findings thus suggest that endogenous B7‐H1 can provide positive costimulatory signals for innate and adaptive immunity leading to protection against intracellular bacterial infection.

24 April 2009 in Lupus
Verified
Journal Article
Closed access
MHMinyoung Her
Minyoung Her
DKD Kim
D Kim
MOM Oh
M Oh
HJH Jeong
H Jeong
Inhak ChoiInhak Choi
Inhak Choi
To investigate the level of costimulating molecules in systemic lupus erythematosus (SLE), we assessed the plasma concentrations of soluble forms of costimulatory molecules such as programmed death-1 (PD-1), B7-H1 (also called PD-L1 or CD274) and inducible costimulator ligand (ICOSL) in patients with SLE. Plasma concentrations of soluble PD-1, B7-H1 and ICOSL were measured by ELISA using plasma samples from 57 SLE patients with or without the active disease, 21 rheumatoid arthritis (RA) patients and 35 healthy subjects. We also evaluated surface ICOSL expression on B cells using flow cytometry to gain a better understanding of ICOSL expression. To compare the level of ICOSL mRNA expression, reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using total RNA from peripheral blood mononuclear cells (PBMCs) isolated from eight healthy subjects and 11 patients with SLE. The concentration of plasma ICOSL was significantly higher in patients with SLE compared with healthy subjects (P = 0.005). Plasma ICOSL concentrations in patients with active SLE were also significantly higher than those of either patients with inactive SLE or patients with RA (P = 0.001, P = 0.015, respectively). Plasma ICOSL concentrations in patients with SLE correlated modestly with the SLE disease activity index score (r = 0.298, P = 0.024). We also found a significant inverse correlation between the soluble ICOSL expression and the surface ICOSL expression on B cells (r = −0.690, P = 0.001). However, ICOSL mRNA levels of patients with SLE were comparable with those of the control subjects. There was also no significant difference in plasma B7-H1 concentrations between groups, and plasma PD-1 was not detectable in any of the groups. The plasma concentration of soluble ICOSL might be correlated to the disease severity of lupus. The increased levels of ICOSL in active lupus suggest that this pathway is involved in the pathogenesis of SLE. The mechanism and physiological role of soluble ICOSL in the pathogenesis of SLE, however, remains to be investigated.

31 January 2021 in BMB Reports
Verified
Journal Article
Open access
PDF file
PYPedram Yadollahi
Pedram Yadollahi
YJYou-Kyoung Jeon
You-Kyoung Jeon
WNWooi Loon Ng
Wooi Loon Ng
Inhak ChoiInhak Choi
Inhak Choi
Pedram Yadollahi, You-Kyoung Jeon, Wooi Loon Ng & Inhak Choi. BMB Reports 2021;54:12-20. https://doi.org/10.5483/BMBRep.2021.54.1.241

1 April 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MKMinsuk Kwon
Minsuk Kwon
CKChang Gon Kim
Chang Gon Kim
HLHoyoung Lee
Hoyoung Lee
Hyunsoo ChoHyunsoo Cho
Hyunsoo Cho
YKYoungun Kim
Youngun Kim
ESEui-Cheol Shin
Eui-Cheol Shin
Purpose: Immune checkpoint inhibitors have shown therapeutic efficacy in various malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown clinical efficacy in multiple myeloma (MM). Experimental Design: Bone marrow (BM) mononuclear cells were obtained from 77 newly diagnosed MM patients. We examined the expression of immune checkpoint receptors in BM CD8+ T cells and their functional restoration by ex vivo treatment with anti-PD-1 and TGF-b inhibitors. Results: We confirmed the upregulation of PD-1 and PD-L1 expression in CD8+ T cells and myeloma cells, respectively, from the BM of MM patients. PD-1-expressing CD8+ T cells from the BM of MM patients co-expressed other checkpoint inhibitory receptors and exhibited a terminally differentiated phenotype. These results were also observed in BM CD8+ T cells specific to myeloma antigens NY-ESO-1 and HM1.24. BM CD8+ T cells from MM patients exhibited reduced proliferation and cytokine production upon T-cell receptor stimulation. However, anti-PD-1 did not increase the proliferation of BM CD8+ T cells from MM patients, indicating that T-cell exhaustion in MM is hardly reversed by PD-1 blockade alone. Intriguingly, anti-PD-1 significantly increased the proliferation of BM CD8+ T cells from MM patients in the presence of inhibitors of TGF-b, which was overexpressed by myeloma cells. Conclusions: Our findings indicate that combined blockade of PD-1 and TGF-b may be useful for the treatment of MM.